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We report the case of a 61-year-old white man with end-stage renal disease secondary to an autosomal dominant polycystic kidney disease. Dialysis therapy was commenced in 2003, and he received a renal transplant from a deceased donor in 2004. His circulating parathormone (PTH) concentration before transplantation was 
287 pg/mL as measured by the Roche Elecsys immunoassay analyser (Mannheim, Germany), in the target of the K/DOQI recommendations (1). The transplanted kidney functioned until 2007, and then failed because of acute cellular rejection (type IIB according to Banff classification). He received standard anti-rejection medication (intravenously steroids and OKT3) but did not respond, lost function of his renal graft and returned to hemodialysis in February 2007. Four months later, the renal graft was removed because of systemic manifestations of rejection. From March to December 2007, plasma PTH concentrations were measured every 3 months again by Roche Elecsys. The results showed a rise of PTH after 7 months on hemodialysis, and this was even more dramatic after 10 months (Table 1). No parathyroid mass was identified by 99Tc-Sestamibi or ultrasound scans. An interference in the PTH assay was thus suspected, and the sample was sent to the reference laboratory where extra-investigations were performed, as already published (2). The treatment of the sample with heterophilic blocking tubes (Scantibodies, Shantee, CA), which removes human anti-animal antibodies, resulted in an important decrease of PTH, from 3748 to 552 pg/mL. Treatment with anti-rheumatoid factor (IBL, Hamburg, Germany) did not result in a significant change in PTH. PTH was then measured by a different second-generation chemiluminescent immunoassay (Liaison, Diasorin, Saluggia, Italy) that uses polyclonal anti-goat antibodies, one directed against the N-terminal (aa 1-34) region, and the other one directed against the C-terminal (aa 39-84) part, which showed a result at 605 pg/mL, not altered by inclusion of human anti-animal antibodies or rheumatoid factor (RF). By contrast the suspect Roche Elecys intact PTH assay uses two murine monoclonal antibodies each of which bind to different epitopes on the PTH molecule; the N- terminal (aa 26-32) portion (3), and the C-terminal fragment (aa 38-84). Thus these two assays use antibodies derived from different animal species which bind to different epitopes on the PTH molecule. This led us to conclude that there was an analytical interference in the PTH determination by Elecsys, and that this interference was because of a human anti-mouse IgM.




TABLE 1.     Evolution of the biological parameters in a hemodialyzed patient who had received OKT3 for a renal-graft rejection in February 2007




In conclusion, physicians should always keep in mind that OKT3 treatment can result in the production of human anti-mouse antibodies. These antibodies can interfere with any immunoassay and give spurious results, leading to unnecessary cost-effective extra-investigations.
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